Global Perspectives in Urothelial Carcinoma (2025) – German Focus

October 7, 2025

The 2025 Global Perspectives in Urothelial Carcinoma is an educational series focused on the latest advancements in Urothelial Carcinoma (UC) designed to meet the educational needs of our global audience. The series will consists of three live webinars presented in English with a focus on three different regions (German, LATAM and Japan). Each activity will include a US based moderator and panel of local faculty to the region, including urologists and a medical oncologist . This 90- minute live virtual activity will explore the evolving therapeutic options for patients with locally advanced (la) or metastatic urothelial carcinoma (mUC), discuss the value of early identification and management of adverse events associated with UC, and the importance of patient education.  Local experts will discuss how AUA and local regional clinical guidelines translate into practice and the various roles played by the multidisciplinary team in the treatment advanced and metastatic urothelial carcinoma.

Presented in English, the activity is of value to the global urologic community.

This live virtual event will offer simultaneous translation in 50+ languages. Powered by an involved AI based technology Wordly, attendees will be able to access the audio and captioning translations in real time to help make the course more accessible to our colleagues around the globe. 

This part of the series is presented by the AUA in partnership with the Deutsche Gesellschaft für Urologie (DGU) and focuses on the latest advancements in Urothelial Carcinoma in Germany.


ACKNOWLEDGEMENTS

Support provided by an independent educational grant from:

  • Astellas and Pfizer, Inc.

Target Audience

  • Urologists

Learning Objectives

After participating in this CME activity, participants will be able to:

  1. Identify new and emerging treatment options in the locally advanced (la)/metastatic urothelial carcinoma (mUC) setting, including combination regimens and optimal sequencing.
  2. Analyze mechanisms of action of novel agents in the la/mUC setting.
  3. Address the roles of the urologist, medical oncologist, radiation oncologist, and other clinicians in delivering holistic, multidisciplinary care to UC patients.
  4. Incorporate AUA and relevant local/regional clinical guidelines updates for UC treatments into practice.
  5. Properly manage adverse events associated with therapies for la and mUC and discuss ways to improve early identification.
  6. Determine appropriate management strategies to reduce the incidence of AEs to minimize morbidity, including identifying methods to leverage multidisciplinary teams and advanced practice providers to achieve these goals.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
06/04/2025
Course expires: 
10/07/2028
Event starts: 
10/07/2025 - 1:00pm EDT
Event ends: 
10/07/2025 - 2:30pm EDT
Rating: 
0

Welcome 

Pre-test 

  • Segment 1:  New and Emerging Treatment Options & Mechanisms of Action of Novel Agents in the la/mUC Setting 
  • Segment 2:  Delivering Holistic, Multidisciplinary Care to UC Patients 
  • Segment 3: Incorporating Guideline into Practice 
  • Segment 4: Managing Adverse Events for la and mUC Therapies 
  • Segment 5: Patient Education

Post-Test 

Q&A Session

EDUCATION COUNCIL DISCLOSURE

PDF iconEducation Council DTL 2025_1.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF iconCOI Review Workgroup DTL 2025_1.pdf

FACULTY DISCLOSURES

NameCompany NameRelationship TypeEnd Date
Bronimann, StephanNo relevant financial relationships to disclose
Burger, Maximilian, Prof. Dr. AstraZeneca GmbHMeeting Participant or LecturerCurrent
Bayer Vital GmbHMeeting Participant or LecturerCurrent
Ferring Arzneimittel GmbHMeeting Participant or LecturerCurrent
Janssen-Cilag GmbHMeeting Participant or LecturerCurrent
MSD Sharp & Dohme GmbHMeeting Participant or LecturerCurrent
Pfizer PHarma GmbHMeeting Participant or LecturerCurrent
Photocure ASA - The Bladder CompanyMeeting Participant or LecturerCurrent
Accord Health Care GmbHScientific Study or TrialCurrent
Medac GmbHMeeting Participant or LecturerCurrent
Birstol-Myers Squibb GmbH & Co KGMeeting Participant or LecturerCurrent
Astellas Pharma GmbHMeeting Participant or LecturerCurrent
Matin, Surena FazeliMerckConsultant or AdvisorCurrent
Ferring PharmaceuticalsScientific Study or TrialCurrent
Shariat, ShahrokhLillyConsultant or AdvisorCurrent
Astra ZenecaConsultant or AdvisorCurrent
Bayer Consultant or AdvisorCurrent
BMSConsultant or AdvisorCurrent
CepheidConsultant or AdvisorCurrent
FerringConsultant or AdvisorCurrent
IpsenConsultant or AdvisorCurrent
JanssenConsultant or AdvisorCurrent
MSD Consultant or AdvisorCurrent
OlympusConsultant or AdvisorCurrent
Pfizer Consultant or AdvisorCurrent
RocheConsultant or AdvisorCurrent
UrogenConsultant or AdvisorCurrent
Thomas, ChristianAstellasMeeting Participant or LecturerCurrent
Johnson and JohnsonConsultant or AdvisorCurrent
BayerMeeting Participant or LecturerCurrent
von Amsberg, GunhildAstrazenecaConsultant or AdvisorCurrent

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

Registration for Global Perspectives in Urothelial Carcinoma (2025) – German Focus is complimentary, however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting [email protected].

To join the live virtual course:

  1. Click on the TAKE COURSE button.
  2. Click “Live Virtual Course” in the Course Progress pane.
  3. Click the link to register in advance.
  4. After registering, you will receive a confirmation email containing information about joining the live virtual course.

Attendee Information & Policies

AUA Anti-Harassment Policy

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at [email protected] or Maureen E. Cones, Esq., AUA General Counsel, at [email protected] or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms. 

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA. 

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.